UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

Trends in immunology, 2016-07, Vol.37 (7), p.462-476

2016

Volltextzugriff (PDF)

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Blood reviews, 2020-11, Vol.44, p.100672-100672, Article 100672

2020

Volltextzugriff (PDF)

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Cold Spring Harbor perspectives in medicine, 2016-06, Vol.6 (6), p.a026336

2016

Volltextzugriff (PDF)

The Mouse Kinome: Discovery and Comparative Genomics of All Mouse Protein Kinases

Proceedings of the National Academy of Sciences - PNAS, 2004-08, Vol.101 (32), p.11707-11712

2004

Volltextzugriff (PDF)

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Molecular cancer therapeutics, 2016-07, Vol.15 (7), p.1568-1579

2016

Volltextzugriff (PDF)

Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors

Journal of medicinal chemistry, 2011-03, Vol.54 (6), p.1789-1811

2011

Volltextzugriff (PDF)

Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity

Molecular cancer research, 2017-11, Vol.15 (11), p.1587-1597

2017

Volltextzugriff (PDF)

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Clinical cancer research, 2009-01, Vol.15 (1), p.110-118

2009

Volltextzugriff (PDF)

Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor

Journal of medicinal chemistry, 2007-02, Vol.50 (4), p.611-626

2007

Volltextzugriff (PDF)

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

Clinical cancer research, 2021-03, Vol.27 (5), p.1526-1537

2021

Volltextzugriff (PDF)

Abstract 1050: Efficacy of AMG 176 in combination with gilteritinib in preclinical models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1050-1050

2021

Volltextzugriff (PDF)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

Journal of experimental & clinical cancer research, 2010-07, Vol.29 (1), p.96-96, Article 96

2010

Volltextzugriff (PDF)

Abstract 2180: AMG 176 exhibits robust antitumor activity in combination with standard of care agents in models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2180-2180

2019

Volltextzugriff (PDF)

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors

Bioorganic & medicinal chemistry letters, 2007-05, Vol.17 (10), p.2886-2889

2007

Volltextzugriff (PDF)

Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6218-6218

2020

Volltextzugriff (PDF)

Abstract 4558: Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4558-4558

2020

Volltextzugriff (PDF)

Abstract 982: LKB1 loss rewires stress signaling-induced apoptotic protein dynamics and sensitizes KRAS -mutant non-small cell lung cancers to combined MAPK + MCL-1 blockade

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.982-982

2021

Volltextzugriff (PDF)

Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2027-2027

2017

Volltextzugriff (PDF)

Abstract 2978: The utilization of a human MCL1 knockin mouse suggests that reductions in B-cells and monocytes may serve as clinically relevant pharmacodynamic markers of MCL1 inhibition

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2978-2978

2018

Volltextzugriff (PDF)

Abstract 3972: Combined inhibition of MCL1 and BCL-2 with AMG 176 and venetoclax induces anti-tumor effects in primary patient samples and models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3972-3972

2018

Volltextzugriff (PDF)

Discovery and in Vivo Evaluation of Macrocyclic Mcl‑1 Inhibitors Featuring an α‑Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere

Journal of medicinal chemistry, 2019-11, Vol.62 (22), p.10258-10271

2019

Volltextzugriff (PDF)

Identifying the determinants of response to MDM2 inhibition

Oncotarget, 2015-04, Vol.6 (10), p.7701-7712

2015

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Animals
(25)
Humans
(23)
Mice
(18)
Oncology
(15)
Rats
(13)
Cell Line, Tumor
(12)
Chemistry, Medicinal
(12)
Female
(12)
Pharmacology & Pharmacy
(12)
Antineoplastic Agents - Pharmacology
(9)
Crystallography, X-Ray
(9)
Models, Molecular
(9)
Structure-Activity Relationship
(9)
Protein Kinase Inhibitors - Pharmacology
(8)
Xenograft Model Antitumor Assays
(8)
Mice, Nude
(7)
Phosphorylation
(7)
Sulfonamides - Pharmacology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

Targeting MCL-1 in hematologic malignancies: Rationale and progress

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

The Mouse Kinome: Discovery and Comparative Genomics of All Mouse Protein Kinases

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors

Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Abstract 1050: Efficacy of AMG 176 in combination with gilteritinib in preclinical models of acute myeloid leukemia

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors

Abstract 2180: AMG 176 exhibits robust antitumor activity in combination with standard of care agents in models of acute myeloid leukemia

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS -Mutant Non-Small Cell Lung Cancer

Abstract 6218: Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor

Abstract 4558: Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)

Abstract 982: LKB1 loss rewires stress signaling-induced apoptotic protein dynamics and sensitizes KRAS -mutant non-small cell lung cancers to combined MAPK + MCL-1 blockade

Abstract 2027: Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models

Abstract 2978: The utilization of a human MCL1 knockin mouse suggests that reductions in B-cells and monocytes may serve as clinically relevant pharmacodynamic markers of MCL1 inhibition

Abstract 3972: Combined inhibition of MCL1 and BCL-2 with AMG 176 and venetoclax induces anti-tumor effects in primary patient samples and models of acute myeloid leukemia

Discovery and in Vivo Evaluation of Macrocyclic Mcl‑1 Inhibitors Featuring an α‑Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere

Identifying the determinants of response to MDM2 inhibition

Suchergebnisse filtern